KRAS inhibitor breakthroughs — the targeted therapies addressing the most frequently mutated oncogene in human cancers (present in approximately 25% of all tumors) that was considered pharmacologically intractable for decades — are reshaping the competitive dynamics of the $47.11 billion oncogene inhibitor market, with the Oncogene Inhibitor Market reflecting KRAS G12C inhibitors as...